259 related articles for article (PubMed ID: 12380640)
1. Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?
Rüegg C; Dormond O; Foletti A
Endothelium; 2002; 9(3):151-60. PubMed ID: 12380640
[TBL] [Abstract][Full Text] [Related]
2. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.
Rüegg C; Dormond O; Mariotti A
Biochim Biophys Acta; 2004 Mar; 1654(1):51-67. PubMed ID: 14984767
[TBL] [Abstract][Full Text] [Related]
3. Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis.
Rüegg C; Mariotti A
Cell Mol Life Sci; 2003 Jun; 60(6):1135-57. PubMed ID: 12861381
[TBL] [Abstract][Full Text] [Related]
4. Regulation of endothelial cell integrin function and angiogenesis by COX-2, cAMP and Protein Kinase A.
Dormond O; Rüegg C
Thromb Haemost; 2003 Oct; 90(4):577-85. PubMed ID: 14515176
[TBL] [Abstract][Full Text] [Related]
5. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
Reinmuth N; Liu W; Ahmad SA; Fan F; Stoeltzing O; Parikh AA; Bucana CD; Gallick GE; Nickols MA; Westlin WF; Ellis LM
Cancer Res; 2003 May; 63(9):2079-87. PubMed ID: 12727823
[TBL] [Abstract][Full Text] [Related]
6. Vascular integrins: therapeutic and imaging targets of tumor angiogenesis.
Rüegg C; Alghisi GC
Recent Results Cancer Res; 2010; 180():83-101. PubMed ID: 20033379
[TBL] [Abstract][Full Text] [Related]
7. Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis.
Boosani CS; Mannam AP; Cosgrove D; Silva R; Hodivala-Dilke KM; Keshamouni VG; Sudhakar A
Blood; 2007 Aug; 110(4):1168-77. PubMed ID: 17426256
[TBL] [Abstract][Full Text] [Related]
8. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma.
Rüegg C; Yilmaz A; Bieler G; Bamat J; Chaubert P; Lejeune FJ
Nat Med; 1998 Apr; 4(4):408-14. PubMed ID: 9546785
[TBL] [Abstract][Full Text] [Related]
9. alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.
Nisato RE; Tille JC; Jonczyk A; Goodman SL; Pepper MS
Angiogenesis; 2003; 6(2):105-19. PubMed ID: 14739617
[TBL] [Abstract][Full Text] [Related]
10. Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatment.
Hsu AR; Veeravagu A; Cai W; Hou LC; Tse V; Chen X
Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):143-58. PubMed ID: 18221059
[TBL] [Abstract][Full Text] [Related]
11. Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells.
Maubant S; Saint-Dizier D; Boutillon M; Perron-Sierra F; Casara PJ; Hickman JA; Tucker GC; Van Obberghen-Schilling E
Blood; 2006 Nov; 108(9):3035-44. PubMed ID: 16835373
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
[TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism.
Cai W; Chen X
Anticancer Agents Med Chem; 2006 Sep; 6(5):407-28. PubMed ID: 17017851
[TBL] [Abstract][Full Text] [Related]
14. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis.
Kumar CC
Curr Drug Targets; 2003 Feb; 4(2):123-31. PubMed ID: 12558065
[TBL] [Abstract][Full Text] [Related]
15. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis.
Dormond O; Foletti A; Paroz C; Rüegg C
Nat Med; 2001 Sep; 7(9):1041-7. PubMed ID: 11533708
[TBL] [Abstract][Full Text] [Related]
16. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide.
Erdreich-Epstein A; Shimada H; Groshen S; Liu M; Metelitsa LS; Kim KS; Stins MF; Seeger RC; Durden DL
Cancer Res; 2000 Feb; 60(3):712-21. PubMed ID: 10676658
[TBL] [Abstract][Full Text] [Related]
17. Distinctive role of integrin-mediated adhesion in TNF-induced PKB/Akt and NF-kappaB activation and endothelial cell survival.
Bieler G; Hasmim M; Monnier Y; Imaizumi N; Ameyar M; Bamat J; Ponsonnet L; Chouaib S; Grell M; Goodman SL; Lejeune F; Rüegg C
Oncogene; 2007 Aug; 26(39):5722-32. PubMed ID: 17369858
[TBL] [Abstract][Full Text] [Related]
18. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets.
Alghisi GC; Rüegg C
Endothelium; 2006; 13(2):113-35. PubMed ID: 16728329
[TBL] [Abstract][Full Text] [Related]
19. Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells.
Yeh CH; Peng HC; Yang RS; Huang TF
Mol Pharmacol; 2001 May; 59(5):1333-42. PubMed ID: 11306719
[TBL] [Abstract][Full Text] [Related]
20. Evidence for the involvement of SDF-1 and CXCR4 in the disruption of endothelial cell-branching morphogenesis and angiogenesis by TNF-alpha and IFN-gamma.
Salvucci O; Basik M; Yao L; Bianchi R; Tosato G
J Leukoc Biol; 2004 Jul; 76(1):217-26. PubMed ID: 15075355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
